Abstract: To determine the relationship between the expression of phosphatase and tensin homologue (PTEN) and epidermal growth factor receptor (EGFR) in metastatic colorectal cancer (mCRC) and the clinical outcome of cetuximab-containing chemotherapy.
INTRODUCTION

C
olorectal cancer is the third most commonly diagnosed cancer in males and the second in females, with an estimated 1.4 million cases and 693,900 deaths occurring in 2012. 1 About 25% of patients with colorectal cancer present with metastases at the time of diagnosis. 2 Metastatic colorectal cancer (mCRC) is associated with a particular poor prognosis. Despite progress in chemotherapy during past decades, the 5-year survival rate for patients with mCRC remains below 10%. 3, 4 Currently, the median survival of patients with mCRC has improved to 24 to 30 months, largely due to the availability of newer treatment options, including the epidermal growth factor receptor (EGFR)-targeted monoclonal antibody (mAb) cetuximab or panitumumab, and the vascular endothelial growth factor-targeted mAb bevacizumab. 5, 6 Several studies have suggested that the anti-EGFRmediated antitumor activity is restricted to patients with wild-type KRAS tumors, and selection of patients for anti-EGFR mAb therapy based on tumor KRAS analysis is a major step toward tailored treatment for mCRC. [7] [8] [9] [10] However, the response rates (RRs) to anti-EGFR mAb treatments range from 40% to 60% when used in combination with chemotherapy. That means that up to 50% of KRAS wild-type patients do not benefit from the EGFR-targeted therapy. [10] [11] [12] Recently, some studies showed that mutations in other downstream effectors of the EGFR signaling pathway, such as BRAF, NRAS, and PIK3CA, seem to be responsible for this phenomenon. 13, 14 The negative selection of mutant genotypes downstream the EGFR modestly improved objective RRs compared with KRAS alone, indicating that additional markers are needed in order to better predict the response to anti-EGFR mAb therapy. 14, 15 In the present study, we assessed the phosphatase and tensin homologue (PTEN) and EGFR status with immunohistochemistry (IHC) in mCRC patients with wild-type KRAS status and their correlation with the outcome of cetuximab treatment. Our objective is to use the results to provide more markers to determine the efficacy of cetuximab therapy for patients with mCRC besides 4 mutations (KRAS, BRAF, NRAS, and PIK3CA) in downstream effectors of the EGFR signaling pathway.
METHODS
Ethics Statement
All procedures were conducted in accordance with the Helsinki declaration, and with approval from the Ethics Committee of the Fujian Provincial Cancer Hospital. Written informed consent was obtained from all participants.
Eligibility
We consecutively analyzed all the mCRC patients who were admitted to the Department of Medical Oncology of Fujian Provincial Cancer Hospital from January 2007 to December 2012. A total of 158 patients with mCRC were included in the study according to the following criteria: Histologically confirmed adenocarcinoma of the colon or rectum and KRAS exon 2 wildtype; A first occurrence of metastatic disease that was deemed to be unresectable with palliative intent; Complete medical records were available; Eastern Cooperative Oncology Group performance status (ECOG PS) between 0 and 2; No prior chemotherapy except for postoperative adjuvant chemotherapy more than 12 months before entry into the study; Adequate functioning bone marrow, liver, and kidneys; Availability of adequate formalinfixed paraffin embedded tumor tissue for biological marker evaluation; All patients had nonrandomly received systemic chemotherapy regimens, including fluorouracil, folinic acid, and irinotecan (FOLFIRI), fluorouracil, folinic acid, and xaliplatin (FOLFOX), of at least 6 cycles; and Patients who were treated with cetuximab were to be continued until disease progression (PD), intolerable toxicity, or patient refusal of further treatment. Patients treated with bevacizumab were not included because there were too few for a meaningful subgroup analysis.
Treatment
The FOLFIRI regimen comprised a 60 to 90-minutes infusion of irinotecan at a dose of 180 mg/m 2 of body-surface area, a 120-minutes infusion of racemic folinic acid at a dose of 400 mg/m Tissue Microarray (TMA)
TMA technology was employed in this study. The colorectal TMAs were prepared from our series of colorectal carcinomas samples according to the method described by Kononen et al. 16 All cases were reviewed and the tumor area was marked on H&E stained slides. Tissue arrays were then constructed by placing 2 mm diameter samples from 60 different tumor samples from each block in a 6 by 10 arrangement, with 1 mm spacing separating each specimen. Cases not represented, damaged, or inadequate on the TMA sections were re-cut from the original blocks.
Immunohistochemistry (IHC)
Immunohistochemical detection of EGFR and PTEN were performed with the use of the BenchMark XT platform (Ventana Automated Systems, Tucson, AZ). The sections were stained with a rabbit anti-EGFR (MaiXin Biotechnologies, China) mab, ready to use, for 90 minutes and with the rabbit anti-PTEN mab (Boster Biological Technology Co. Ltd, lot: BA1377, China) at a dilution of 1:400, for 36 minutes. Immune complexes were detected with the use of an optiVIEW 3 0 3-diaminobenzidine (DAB) detection kit with DAB as the chromogen.
Evaluation of Immunostaining
The sections were scored semiquantitatively with light microscopy by 2 pathologists without any prior knowledge about the clinical history of the patients. The EGFR membrane expression and PTEN cytoplasm and nuclear expression levels were scored semiquantitatively as previously described. [17] [18] [19] The intensity of the immunostaining was classified into 4 categories: 0 ¼ no staining or only a nonspecific background color, 1 ¼ light yellow, 2 ¼ yellow or deep yellow, and 3 ¼ brown or tan. The percentage of tumor cells showing the different staining intensities were visually assessed. The IHC score of immunoreactivity was obtained by multiplying the intensity and percentage of cells staining. We generate an EGFR and a PTEN IHC score on a continuous scale of 0 to 300.
EGFR histochemical scores were divided into 2 groups, cases with scores of 0 to 199 were defined as the low-expression group, and cases with scores of 200 to 300 were defined as the high-expression group. PTEN histochemical scores were separated into PTEN loss (cases with a score of 0) group or PTENnormal (cases with score >0) group.
Evaluation of Efficacy and Toxicity
The patients were evaluated with computed tomography or magnetic resonance imaging scans before systemic treatment and every 1 to 2 months until progression, according to the Response Evaluation Criteria in Solid Tumors version 1.1, or death. 20 Overall survival (OS) was defined from the date of initial treatment to death from any cause.
A complete blood cell count and measurements of liver and renal function were assessed at least once a week during treatment. Nonhematological toxicities were also verified at least once a week by patient interview and physical examination. Toxicity was graded according to the National Cancer Institute Common Toxicity Criteria version 3.0. 21 
Statistical Methods
Statistical analysis was performed with the SPSS software (Version 21.0, SPSS). Comparisons between proportions were analyzed using the x 2 test and the Fisher exact probability test. The OS variables were estimated by the Kaplan-Meier method and survival curves were plotted. Two-sided log-rank tests were used to compare survival rates between groups. Multivariate analyses using the Cox proportional hazards regression model were performed to assess the impact of the variables on OS.
RESULTS
Patient Characteristics and Clinical Data
A total of 158 mCRC patients with wild-type KRAS status were enrolled in the study. Fifty-one patients received chemotherapy combined with cetuximab; 25 patients received cetuximab as first-line, and 26 patients received cetuximab as second-line therapy. One hundred and seven patients received chemotherapy alone. For 158 patients, 28 patients received only first-line chemotherapy, and 130 patients received second-line chemotherapy after disease progression. The patient characteristics are summarized in Table 1 .
EGFR and PTEN Expression
The EGFR protein expression in the tumor tissues was broadly homogenous and was detected mainly at the cell membrane. The PTEN protein expression was detected mainly in the cytoplasm, although occasional nuclear expression was seen (Figure 1 ). High-expression of EGFR protein, a histochemical scores !200, was documented by IHC in 60 of 158 samples (38.0%), while with normal PTEN expression a histochemical score >0, was documented in 94 of 158 sample (59.5%). There were no significant clinical differences between the EGFR or PTEN expression and clinicopathologic features except that PTEN loss was significantly association with the histological grade, P ¼ 0.001. Various patient characteristics according to EGFR and PTEN are shown in Table 2 .
Survival Analysis and Objective Response Rate
For the 158 patients, the median OS was 16.0 months, 95% CI ¼ (14.68-17.32), and the 1-year survival rate and 2-year survival rate were 73.4% and 15.2%, respectively (Figure 2A ). In the univariate analysis, ECOG PS, chemotherapy AE cetuximab, lines of chemotherapy, EGFR status, and PTEN status were associated with OS, while the sex, age, and histological grade were not correlated with OS (Table 3 ). The median OS of patients in the chemotherapy 
FIGURE 2. Kaplan-Meier curves for overall survival (OS) in 158 patients (A). OS in the patients received chemotherapy combined with or not cetuximab (B).
To confirm the importance of the cetuximab therapy for the KRAS wild-type mCRC patients when correlated with the expression of EGFR or PTEN, we divided the 158 patients into a chemotherapy þ cetuximab group and a chemotherapy group. For the patients in the chemotherapy þ cetuximab group, the median OS of patients with high-expression of EGFR the median OS was higher than in the patients with low expression; 25.0 versus 19.0 months, P ¼ 0.002. Patients with normal PTEN had a longer median OS than patients with loss of PTEN; 24.0 versus 19.0 months, P ¼ 0.026 ( Figure 3A, B) . In the chemotherapy group, the median OS was not significantly different between the EGFR high-expression and low-expression patients, P ¼ 0.616, while patients with normal PTEN had longer median OS than those with loss of PTEN loss, P ¼ 0.036 ( Figure 4A, B) .
Furthermore, analysis of the objective RR for the chemotherapy þ cetuximab group showed that the proportion of patients who achieved a response was higher in the EGFR high group than in the EGFR low group; 14/20 (70.0%) versus 11/31 (35.5%) P ¼ 0.055. The overall response rate (ORR) was higher in the normal PTEN group than in the loss of PTEN group; 17/30 (56.7%) versus 8/21 (38.1%), P ¼ 0.048 (Table 4) .
In the multivariate analysis, considering chemotherapy AE cetuximab was the most statistically significant factor, we adjust chemotherapy AE cetuximab as a correction factor, variables that included ECOG PS, lines of chemotherapy, EGFR status, PTEN status, chemotherapy AE cetuximab, and the interaction of EGFR or PTEN and chemotherapy AE cetuximab were tested to determine their independent effect on OS. The ECOG PS, EGFR status, chemotherapy AE cetuximab, and the interaction of EGFR or PTEN and chemotherapy AE cetuximab were independent prognostic factors for OS (Table 5) , which were consistent with the results of the univariate subgroup analysis.
DISCUSSION
In this study, we have characterized high tumor EGFR and normal PTEN expression as predictive biomarkers that, independently of tumor histology, EGOG PS, or regimens of chemotherapy, defines patients with wild-type KRAS mCRC who are most likely to derive a survival benefit and objective response from the addition of cetuximab to chemotherapy. The EGFR-directed mAb cetuximab was approved to treat patients with chemo-refractory mCRC in 2004 and achieved objective RRs of approximately 10% when used as monotherapy for irinotecan-refractory and/or oxaliplatin-refractory mCRC. 22 Since then, a rapidly accumulating body of knowledge has indicated that resistance to EGFR blockade in mCRC is related to constitutive activation of signaling pathways downstream of the EGFR, particularly interesting is the role of mutations within the KRAS oncogene due to their association with the lack of a benefit from anti-EGFR mAb therapy. [23] [24] [25] Because not all KRAS wild-type patients benefit from treatment with EGFR-directed therapy, basic and clinical research has been conducted to identify additional mutations which would be resistant, and that could account for the heterogeneity in the clinical response; such as BRAF, NRAS, and PIK3CA. These markers are good negative predictive factors, but scientists and clinicians would prefer to identify the positive predictive factors of response to anti-EGFR therapy which would be much more useful than negative predictors in the clinical setting. 26, 27 The EGFR gene copy number, as determined by FISH analysis, seemed to correlate with the response to anti-EGFR mAbs for patients with wild-type KRAS mCRC in several studies. 18, 28, 29 Gene amplification may lead to protein overexpression. 30, 31 Findings from the FLEX study showed that high EGFR expression determined by IHC is a tumor biomarker that can predict the survival benefit from the addition of cetuximab to first-line chemotherapy in patients with advanced nonsmall cell lung cancer. 17 In our study, we assessed the EGFR status by IHC according to the histochemical score with respect to the percentage of positive cells and staining intensity, which showed that patients with high EGFR expression who received chemotherapy combined with cetuximab, gained higher ORR and survival benefits. However, for the wild-type mCRC patients who received chemotherapy alone, EGFR expression was not associated with OS. This was confirmed by the multivariate analysis and the results are in accordance with previous studies. 18, 29, 32 We did not use the FISH analysis for EGFR because the colorectal sample came from the record of our hospital between January 2007 and December 2012, so that most pathological samples are over 5-years old. This means that there may be false-negative results in the FISH assay. As a consequence, we selected only the immunohistochemical test.
PTEN is a tumor-suppressor protein that regulates the activity of PI3K/AKT by converting PIP3 back to PIP2, the loss of PTEN results in AKT-mediated hyper-phosphorylation, which protects cells from apoptosis and makes them resistance to anti-EGFR therapy. [33] [34] [35] We have also shown that PTEN expression was associated with OS and ORR in a chemotherapy combined with cetuximab cohort. Furthermore, the PTEN status was significantly related with the histological grade, and interaction of PTEN/chemotherapy AE cetuximab was an independent prognostic factor for mCRC patients with wild-type KRAS. It means that PTEN loss may be a potential predictor for the cetuximab therapy outcome. This result is consistent with basic research and previous translational research.
Based on our findings, we think that for colorectal cancer patients with wild type KRAS, the test for the PTEN gene helps to estimate the prognosis of patients. As for patients who are going to use cetuximab, further tests of PTEN and EGFR are conducive to better define the patients who will respond effectively to the treatment, apart from using past mutation tests like NRAS, BRAF, and PIK3CA.
Interpreting EGFR and PTEN data can be challenging, because IHC can produce variable results. A standard universally accepted EGFR and PTEN testing and scoring system, to allow for comparisons of data worldwide, has yet to be established. According to early research, we chose the semiquantitative IHC, and positive results have been observed by our research group. Compared to the expensive FISH assay, the IHC test is not only more economical but it will also be easy to popularize. If future research confirms these promising results, then testing for EGFR over-expression and normal PTEN will further identify the patient subgroups that will benefit from anti-EGFR therapy.
Our results are limited by the retrospective nature of the analysis, and the small sample size of the cetuximab group. Therefore, a treatment model for using the EGFR and PTNE status expression as a guide for anti-EGFR therapy for mCRC patients with wild-type KRAS needs further investigation with an expanded sample size in further prospective clinical studies.
In conclusion, this study indicated that chemotherapy combined with cetuximab demonstrated encouraging antitumor activity for mCRC patients with wild-type KRAS status. Especially, those who harbored high EGFR expression or normal PTEN expression were more likely to benefit from such a treatment strategy.
